Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network

Paul A. Carpenter; Brent R. Logan; Stephanie J. Lee; Daniel J. Weisdorf; Laura Johnston; Luciano J. Costa; Carrie L. Kitko; Javier Bolaños‐Meade; Amin M. Alousi; Mary M. Horowitz; Sunil Abhyankar; Edmund K. Waller; Adam Mendizabal; Yanli Wang; Aleksandr Lazaryan; Shelly L. Carter; Eneida R. Nemecek; Steven Z. Pavletic; Corey Cutler; Mukta Arora

doi:10.1016/j.bbmt.2015.11.336

Abstract

To compare the proportion of subjects with cGVHD who had treatment success, defined as alive with complete or partial response (CR+PR) and no receipt of secondary systemic immunosuppressive therapy, at 6 months post randomization to PDN/SRL or PDN/SRL/CNI.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Carpenter et al. (2016) studied this question.

synapsesocial.com/papers/6a776cbed8eb58afc2bddb26 https://doi.org/10.1016/j.bbmt.2015.11.336

View Full Paper

Ask AI

Bookmark

Share

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network

Abstract

Discussion

Cite This Study

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network

Abstract

Discussion

Cite This Study

Keep reading

More from Biology of Blood and Marrow Transplantation

Keep reading

More from Biology of Blood and Marrow Transplantation